Cargando…

A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma

BACKGROUND AND AIMS: Sorafenib is the first molecular targeted drug approved for the treatment of advanced hepatocellular carcinoma (HCC) and is a potent small molecule inhibitor of multiple kinases. Combination therapy with sorafenib and other cytotoxic agents for HCC may result in additive antican...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sho, Takuya, Nakanishi, Mitsuru, Morikawa, Kenichi, Ohara, Masatsugu, Kawagishi, Naoki, Izumi, Takaaki, Umemura, Machiko, Ito, Jun, Nakai, Masato, Suda, Goki, Ogawa, Koji, Chuma, Makoto, Meguro, Takashi, Nakamura, Michio, Nagasaka, Atsushi, Horimoto, Hiromasa, Yamamoto, Yoshiya, Sakamoto, Naoya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629128/ https://www.ncbi.nlm.nih.gov/pubmed/28573606 http://dx.doi.org/10.1007/s40268-017-0187-7

Ejemplares similares

L‐Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis
por: Ohara, Masatsugu, et al.
Publicado: (2018)

Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases
por: Sho, Takuya, et al.
Publicado: (2018)

Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis
por: Kawagishi, Naoki, et al.
Publicado: (2018)

The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment
por: Suda, Goki, et al.
Publicado: (2018)

Baseline angiopoietin‐2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma
por: Shigesawa, Taku, et al.
Publicado: (2020)

Tri-antennary tri-sialylated mono-fucosylated glycan of alpha-1 antitrypsin as a non-invasive biomarker for non-alcoholic steatohepatitis: a novel glycobiomarker for non-alcoholic steatohepatitis
por: Ogawa, Koji, et al.
Publicado: (2020)

Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real‐world setting
por: Sho, Takuya, et al.
Publicado: (2019)

Low Baseline CXCL9 Predicts Early Progressive Disease in Unresectable HCC with Atezolizumab Plus Bevacizumab Treatment
por: Hosoda, Shunichi, et al.
Publicado: (2022)

Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
por: Suzuki, Kazuharu, et al.
Publicado: (2022)

Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI
por: Kubo, Akinori, et al.
Publicado: (2021)

Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150
por: Sho, Takuya, et al.
Publicado: (2022)

Pre-sarcopenia and Mac-2 binding protein glycosylation isomer as predictors of recurrence and prognosis of early-stage hepatocellular carcinoma
por: Nakai, Masato, et al.
Publicado: (2022)

Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma
por: Shigesawa, Taku, et al.
Publicado: (2021)

Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C
por: Kawagishi, Naoki, et al.
Publicado: (2021)

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients
por: Nakai, Masato, et al.
Publicado: (2022)

Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C
por: Kawagishi, Naoki, et al.
Publicado: (2023)

Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment
por: Suda, Goki, et al.
Publicado: (2016)

Treatment of hepatitis C in special populations
por: Suda, Goki, et al.
Publicado: (2018)

Possible correlation between increased serum free carnitine levels and increased skeletal muscle mass following HCV eradication by direct acting antivirals
por: Tokuchi, Yoshimasa, et al.
Publicado: (2021)

Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia
por: Yoshida, Sonoe, et al.
Publicado: (2021)

Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma
por: Yang, Zijian, et al.
Publicado: (2022)

Palmitoylethanolamide Ameliorates Carbon Tetrachloride-Induced Liver Fibrosis in Rats
por: Ohara, Masatsugu, et al.
Publicado: (2018)

Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma
por: Yang, Zijian, et al.
Publicado: (2023)

Coexistence of muscle atrophy and high subcutaneous adipose tissue radiodensity predicts poor prognosis in hepatocellular carcinoma
por: Ohara, Masatsugu, et al.
Publicado: (2023)

Extracellular Vesicles from Amnion-Derived Mesenchymal Stem Cells Ameliorate Hepatic Inflammation and Fibrosis in Rats
por: Ohara, Masatsugu, et al.
Publicado: (2018)

Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report
por: Umemura, Machiko, et al.
Publicado: (2021)

Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapy
por: Kawagishi, Naoki, et al.
Publicado: (2022)

Potential Correlation between Changes in Serum FGF21 Levels and Lenvatinib-Induced Appetite Loss in Patients with Unresectable Hepatocellular Carcinoma
por: Kohya, Risako, et al.
Publicado: (2023)

Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication
por: Nakai, Masato, et al.
Publicado: (2022)

Successful treatment with sorafenib for sunitinib‐refractory metastatic papillary renal cell carcinoma: Potential impact of Raf overexpression on predicting the efficacy of sorafenib
por: Morinaga, Ryota, et al.
Publicado: (2018)

Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma
por: Deng, Lifen, et al.
Publicado: (2013)

Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy
por: Sho, Takuya, et al.
Publicado: (2021)

Small-molecule inhibitor cocktail promotes the proliferation of pre-existing liver progenitor cells
por: Fu, Qingjie, et al.
Publicado: (2022)

Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma
por: Liang, Run-Bin, et al.
Publicado: (2021)

Clinicopathological Examination of Metaplastic Spindle Cell Carcinoma of the Breast: Case Series
por: Ishizuka, Yumiko, et al.
Publicado: (2021)

Macrophage-Derived Extracellular Vesicles Induce Long-Lasting Immunity Against Hepatitis C Virus Which Is Blunted by Polyunsaturated Fatty Acids
por: Cai, Chengcong, et al.
Publicado: (2018)

Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma
por: Takada, Hitomi, et al.
Publicado: (2018)

Cerebral hemorrhage due to amyloid angiopathy that was difficult to differentiate from breast cancer metastasis: a case report
por: Uomori, Toshitaka, et al.
Publicado: (2021)

Clinicopathological Features Related to the Efficacy of CDK4/6 Inhibitor-Based Treatments in Metastatic Breast Cancer
por: Shikanai, Ayana, et al.
Publicado: (2022)

Genomic profiling of intestinal/mixed‐type superficial non‐ampullary duodenal epithelial tumors
por: Miyamoto, Shuichi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3upi94ke43dlemc2p66og8ch5a